Amylyx Pharmaceuticals announced that its Phase 3 LUCIDITY trial met all primary and secondary endpoints, demonstrating a statistically significant 55% reduction in Level 2 and Level 3 hypoglycemic events compared to placebo for avexitide in patients with post-bariatric hypoglycemia. The drug was generally well-tolerated with no treatment-related serious adverse events. The company is preparing for New Drug Application submission to the FDA by the end of 2026, aiming for a potential commercial launch in 2027 if approved. Amylyx Pharmaceuticals operates in the biopharmaceutical industry and develops therapies for rare diseases.
